More on AARD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.74 |
|
|||
| Open | $5.58 | ||||
| 52 Wk High | $0.45 | ||||
| 52 Wk Low | $0.35 | ||||
| Day High | $6.00 | ||||
| Day Low | $5.58 | ||||
| P/E | N/A | ||||
| EPS | $-0.27 | ||||
| Volume | 350,967 | ||||
- Aardvark Therapeutics Inc (AARD) PT Lowered to $21 at Oppenheimer
- Aardvark Therapeutics Inc (AARD) PT Lowered to $21 at BofA Securities
- H.C. Wainwright Downgrades Aardvark Therapeutics Inc (AARD) to Neutral
- Aardvark Therapeutics Inc (AARD) PT Lowered to $9 at BTIG
- Stifel Downgrades Aardvark Therapeutics Inc (AARD) to Hold
- Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight
- Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight
- RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform
- Form 8-K Aardvark Therapeutics, For: Feb 27
- Aardvark Therapeutics pauses phase 3 trial due to cardiac safety signals
Entities mentioned with AARD
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- RBC Capital | View Related Stories »
- Earnings | View Related Stories »
- Morgan Stanley | View Related Stories »
- IPO | View Related Stories »
- Show More...
